Global Epidemiology, Janssen Research and Development, LLC, Titusville, New Jersey, USA.
Real World & Late Phase, Syneos Health, Morrisville, North Carolina, USA.
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5711. doi: 10.1002/pds.5711. Epub 2023 Oct 18.
Most pregnant people take at least one medication during gestation or while breastfeeding, however data are lacking on the safety of medication use in these populations. We conducted a landscape review of real-world data sources specific to medication use in pregnancy and breastfeeding populations that have met, or have potential to meet, health authorities' requirements for post-authorization safety studies.
A 2-phase approach identified data sources from literature, publicly available registers of non-interventional post-authorization studies of pregnant women, existing database inventories, and emerging data sources known to the authors.
Required key attributes were assessed according to current regulatory guidance, resulting in selection of 49 suitable data sources. All global regions were represented, with North America (37%) and Europe (33%) most common; 12% of the data sources included pregnancy information from low-to middle-income countries. Administrative healthcare claims (25%) and electronic healthcare records (21%) comprised the largest types of data sources. Across data sources, 53% were managed by national or regional governments, 27% by industry, and 20% by academic institutions. Maternal age, diagnoses, prenatal care, and reproductive history were available in most, whereas fewer included demographic data (e.g., race/ethnicity). Breastfeeding data were collected in 37% of the final data sources.
We conducted a systematic approach to data source evaluation of pregnancy and breastfeeding to be used as a resource for investigators to consider when designing pregnancy-related research studies to satisfy regulatory requirements.
大多数孕妇在妊娠或哺乳期至少会服用一种药物,但关于这些人群药物使用安全性的数据却很缺乏。我们对专门针对妊娠和哺乳期人群用药的真实世界数据来源进行了全景式回顾,这些数据来源已经满足或有可能满足药品监督管理部门对上市后安全性研究的要求。
采用两阶段方法,从文献、非干预性上市后妊娠妇女研究的公开可用登记处、现有数据库清单以及作者已知的新兴数据源中确定数据源。
根据现行监管指南评估了所需的关键属性,从而选择了 49 个合适的数据源。所有全球区域都有代表,其中北美(37%)和欧洲(33%)最为常见;12%的数据源包含来自中低收入国家的妊娠信息。行政医疗保健索赔(25%)和电子医疗记录(21%)是最大的数据源类型。在数据源中,53%由国家或地区政府管理,27%由行业管理,20%由学术机构管理。大多数数据源都可以获得产妇年龄、诊断、产前护理和生育史等信息,而较少的数据源包括人口统计学数据(如种族/民族)。37%的最终数据源收集了母乳喂养数据。
我们对妊娠和哺乳的数据源进行了系统的评估,以供研究人员在设计与妊娠相关的研究时考虑,以满足监管要求。